Search research articles
Contact Us
Filters
Showing results (61-70 of 78) with videos related to
Page
of 8
Sort By:
European Urology Oncology
|
April 4, 2024
Papillary Renal Cell Carcinoma: Outcomes for Patients Receiving First-line Immune-based Combinations or Tyrosine Kinase Inhibitors from the ARON-1 Study
Francesco Massari, Veronica Mollica, Ondrej Fiala, et al.
International Journal of Cancer
|
November 4, 2025
Toxicity-related immunotherapy discontinuation and outcome in patients with advanced renal cell carcinoma treated with immune-based combinations (ARON-1 study)
Javier Molina-Cerrillo, Giandomenico Roviello, Maria T Bourlon, et al.
Clinical and Experimental Medicine
|
November 2, 2023
Bone targeting agents, but not radiation therapy, improves survival in patients with bone metastases from advanced urothelial carcinoma receiving pembrolizumab: results from the ARON-2 study
Matteo Santoni, Francesco Massari, Hideki Takeshita, et al.
Prostate Cancer and Prostatic Diseases
|
January 7, 2026
Enzalutamide in metastatic hormone-sensitive prostate cancer: results from the international, multicentre, real-world ARON-3 study
Thomas Büttner, Mimma Rizzo, Laura Bernal Vaca, et al.
Targeted Oncology
|
May 5, 2024
Real-World Impact of Upfront Cytoreductive Nephrectomy in Metastatic Non-Clear Cell Renal Cell Carcinoma Treated with First-Line Immunotherapy Combinations or Tyrosine Kinase Inhibitors (A Sub-Analysis from the ARON-1 Retrospective Study)
Ondřej Fiala, Sebastiano Buti, Aristotelis Bamias, et al.
JAMA Oncology
|
October 21, 2021
Clinical Activity and Safety of Cabozantinib for Brain Metastases in Patients With Renal Cell Carcinoma
Laure Hirsch, Nieves Martinez Chanza, Subrina Farah, et al.
Clinical & Experimental Metastasis
|
February 20, 2025
Concomitant medications in patients with metastatic urothelial carcinoma receiving enfortumab vedotin: real-world data from the ARON-2<sup>EV</sup> study
Ondřej Fiala, Sebastiano Buti, Kazutoshi Fujita, et al.
Targeted Oncology
|
September 17, 2024
Real-World Primary Resistance to First-Line Immune-Based Combinations in Patients with Advanced Renal Cell Carcinoma (ARON-1)
Daniele Santini, Haoran Li, Giandomenico Roviello, et al.
Cancer Immunology, Immunotherapy : CII
|
May 27, 2025
Pembrolizumab-axitinib versus nivolumab-cabozantinib as first-line therapy in patients with metastatic renal cell carcinoma: a retrospective real-world comparison (ARON-1)
Matteo Santoni, Giandomenico Roviello, Enrique Grande, et al.
European Journal of Cancer (Oxford, England : 1990)
|
September 23, 2025
<sup>177</sup>Lu-PSMA vs. cabazitaxel in patients with castration-resistant prostate cancer: Real-world efficacy and safety data from the ARON-3 study
Philipp Mandel, Daniel Groener, Giulia Follacchio, et al.
Page
of 8
Search research articles
Search
Showing results (61-70 of 78) with videos related to
Sort By:
Page
of 8
European Urology Oncology
|
April 4, 2024
Papillary Renal Cell Carcinoma: Outcomes for Patients Receiving First-line Immune-based Combinations or Tyrosine Kinase Inhibitors from the ARON-1 Study
Francesco Massari, Veronica Mollica, Ondrej Fiala, et al.
International Journal of Cancer
|
November 4, 2025
Toxicity-related immunotherapy discontinuation and outcome in patients with advanced renal cell carcinoma treated with immune-based combinations (ARON-1 study)
Javier Molina-Cerrillo, Giandomenico Roviello, Maria T Bourlon, et al.
Clinical and Experimental Medicine
|
November 2, 2023
Bone targeting agents, but not radiation therapy, improves survival in patients with bone metastases from advanced urothelial carcinoma receiving pembrolizumab: results from the ARON-2 study
Matteo Santoni, Francesco Massari, Hideki Takeshita, et al.
Prostate Cancer and Prostatic Diseases
|
January 7, 2026
Enzalutamide in metastatic hormone-sensitive prostate cancer: results from the international, multicentre, real-world ARON-3 study
Thomas Büttner, Mimma Rizzo, Laura Bernal Vaca, et al.
Targeted Oncology
|
May 5, 2024
Real-World Impact of Upfront Cytoreductive Nephrectomy in Metastatic Non-Clear Cell Renal Cell Carcinoma Treated with First-Line Immunotherapy Combinations or Tyrosine Kinase Inhibitors (A Sub-Analysis from the ARON-1 Retrospective Study)
Ondřej Fiala, Sebastiano Buti, Aristotelis Bamias, et al.
JAMA Oncology
|
October 21, 2021
Clinical Activity and Safety of Cabozantinib for Brain Metastases in Patients With Renal Cell Carcinoma
Laure Hirsch, Nieves Martinez Chanza, Subrina Farah, et al.
Clinical & Experimental Metastasis
|
February 20, 2025
Concomitant medications in patients with metastatic urothelial carcinoma receiving enfortumab vedotin: real-world data from the ARON-2<sup>EV</sup> study
Ondřej Fiala, Sebastiano Buti, Kazutoshi Fujita, et al.
Targeted Oncology
|
September 17, 2024
Real-World Primary Resistance to First-Line Immune-Based Combinations in Patients with Advanced Renal Cell Carcinoma (ARON-1)
Daniele Santini, Haoran Li, Giandomenico Roviello, et al.
Cancer Immunology, Immunotherapy : CII
|
May 27, 2025
Pembrolizumab-axitinib versus nivolumab-cabozantinib as first-line therapy in patients with metastatic renal cell carcinoma: a retrospective real-world comparison (ARON-1)
Matteo Santoni, Giandomenico Roviello, Enrique Grande, et al.
European Journal of Cancer (Oxford, England : 1990)
|
September 23, 2025
<sup>177</sup>Lu-PSMA vs. cabazitaxel in patients with castration-resistant prostate cancer: Real-world efficacy and safety data from the ARON-3 study
Philipp Mandel, Daniel Groener, Giulia Follacchio, et al.
Page
of 8